BioStock: Chordate Medical’s CEO on the rights issue outcome and way forward

Chordate Medical has now announced the outcome of the rights issue that was completed on February 17. The issue was subscribed to approximately 79.9 per cent in total, of which around 18.4 per cent by guarantee commitments. This means that the company will receive approximately SEK 17.7 million before deduction of issue costs. 

Read the full article at biostock.se:

https://www.biostock.se/en/2025/02/chordate-medicals-ceo-on-the-rights-issue-outcome-and-way-forward/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se